ArticleESMO open2026
Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUncommon EGFR mutations (ucEGFR mut) account for 10%-15% of epidermal growth factor receptor (EGFR) oncogenic alterations in non-small cell lung cancer (NSCLC) and display heterogeneous sensitivity to EGFR tyrosine kinase inhibitors. MATERIALS AND
methodsClinical, pathological, and molecular data from patients with advanced NSCLC harboring ucEGFR mut (excluding ex20 insertions) and treated with first-line osimertinib were retrospectively collected from the Italian ATLAS registry.
resultsFrom January 2019 to January 2025, 212 patients were included. Median age was 69 years (range 24-90); 61.3% were female and 47.6% had a smoking history. Exon 19 deletions/insertions (ex19 delins) were the most frequent ucEGFR mut (55.7%), followed by L816Q (10.8%), G719X (8.5%), and D761N (7.5%). Tumor protein p53 and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) comutations were present in 43.3% and 10.4% of cases. The overall response rate (ORR) was 66% [95% confidence interval (CI) 58-73], median progression-free survival (mPFS) was 18.3 months (95% CI 14.6-19.7), and median overall survival (mOS) was 34.5 months (95% CI 26.1-42.9). Patients with ex19 delins showed superior outcomes versus other ucEGFR mut: ORR (74.3% versus 55%, P = 0.007), mPFS (25.3 versus 12.6 months, P = 0.001), and mOS (41.7 versus 30.4 months, P = 0.03), as well as different resistance mechanisms. Targetable acquired alterations (mesenchymal-epithelial transition amplification and C797S mutations) were detected predominantly in patients with ex19 delins, leading to the use of second-line molecularly matched therapies mainly in this subgroup. Patients with ex19 delins showed similar survival outcomes (25.3 versus 25.4 months, P = 0.55) and resistance patterns compared with a cohort of patients harboring the common exon 19 deletion (ELREA) extracted from the ATLAS registry. Among ex19 delins, variants starting at codon 746 achieved longer survival compared with those starting at codon 747.
conclusionsOsimertinib exhibited meaningful differences in efficacy and resistance mechanisms across distinct ucEGFR mut. Notably, ex19 delins showed comparable survival outcomes and resistance patterns to classical ex19 deletions, albeit with heterogeneous osimertinib sensitivity depending on the deletion-insertion starting codon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.